Developing epigenetic diagnostics and therapeutics for brain disorders

Irfan A. Qureshi, Mark F. Mehler

Research output: Contribution to journalReview articlepeer-review

21 Scopus citations


Perturbations in epigenetic mechanisms have emerged as cardinal features in the molecular pathology of major classes of brain disorders. We therefore highlight evidence which suggests that specific epigenetic signatures measurable in central - and possibly even in peripheral tissues - have significant value as translatable biomarkers for screening, early diagnosis, and prognostication; developing molecularly targeted medicines; and monitoring disease progression and treatment responses. We also draw attention to existing and novel therapeutic approaches directed at epigenetic factors and mechanisms, including strategies for modulating enzymes that write and erase DNA methylation and histone/chromatin marks; protein-protein interactions responsible for reading epigenetic marks; and non-coding RNA pathways.

Original languageEnglish (US)
Pages (from-to)732-741
Number of pages10
JournalTrends in Molecular Medicine
Issue number12
StatePublished - Dec 2013


  • Bromodomain
  • Epigenomic
  • Exosome
  • Glioma
  • Histone deacetylase
  • Long non-coding RNA
  • MicroRNA

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology


Dive into the research topics of 'Developing epigenetic diagnostics and therapeutics for brain disorders'. Together they form a unique fingerprint.

Cite this